SpringerLink
Log in

Positronen-Emissionstomographie bei neuroendokrinen Tumoren

  • Chapter
  • First Online:
Nuklearmedizin bei endokrinen Erkrankungen

  • 109 Accesses

Zusammenfassung

Die Positronen-Emissionstomographie von neuroendokrinen Tumoren (NETs) hat die Bewertung dieser Tumoren im Vergleich zur konventionellen Bildgebung und zur Szintigraphie verbessert. Die am häufigsten verwendeten Radiotracer für die Positronenbildgebung von NETs sind radiomarkierte Somatostatinanaloga, aber auch andere Tracer wie Glukose- und Aminosäureanaloga können verwendet werden. Entscheidungen bezüglich jedes zu verwendenden Radiotracers beinhalten Tumorcharakteristika und erwartete Ergebnisse. Ihre Verwendung kann die Erkennung von Läsionen, die Stadieneinteilung der Krankheit und die Auswahl von Patienten für die Radionuklidtherapie umfassen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
EUR 29.95
Price includes VAT (France)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
EUR 34.99
Price includes VAT (France)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
EUR 44.36
Price includes VAT (France)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  1. Evangelista L, Ravelli I, Bignotto A, Cecchin D, Zucchetta P. Ga-68 DOTA-peptides and F-18 FDG PET/CT in patients with neuroendocrine tumor: a review. Clin Imaging. 2020;67:113–6.

    Article  PubMed  Google Scholar 

  2. Barrio M, Czernin J, Fanti S, Ambrosini V, Binse I, Du L, et al. The impact of somatostatin receptor–directed PET/CT on the management of patients with neuroendocrine tumor: a systematic review and meta-analysis. J Nucl Med. 2017;58(5):756–61.

    Article  PubMed  Google Scholar 

  3. Hofman MS, Hicks RJ. Changing paradigms with molecular imaging of neuroendocrine tumors. Discov Med. 2012;14(74):71–81.

    PubMed  Google Scholar 

  4. Desai H, Borges-Neto S, Wong TZ. Molecular imaging and therapy for neuroendocrine tumors. Curr Treat Options Oncol. 2019;20(10):78.

    Article  PubMed  Google Scholar 

  5. Johnbeck CB, Knigge U, Kjær A. PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature. Future Oncol. 2014;10(14):2259–77.

    Article  CAS  PubMed  Google Scholar 

  6. Delpassand ES, Ranganathan D, Wagh N, Shafie A, Gaber A, Abbasi A, et al. 64Cu-DOTATATE PET/CT for imaging patients with known or suspected somatostatin receptor–positive neuroendocrine tumors: results of the first U.S. prospective, reader-masked clinical. J Nucl Med. 2020;61(6):890–6.

    Google Scholar 

  7. Reubi JC, Schär J-C, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med Mol Imaging. 2000;27(3):273–82.

    Article  CAS  Google Scholar 

  8. Mojtahedi A, Thamake S, Tworowska I, Ranganathan D, Delpassand ES. The value of 68Ga-DOTATATE PET/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature. Am J Nucl Med Mol Imaging. 2014;4(5):426.

    PubMed  PubMed Central  Google Scholar 

  9. Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJM, van Eijck CHJ, Valkema R, et al. Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer. 2010;17(1):R53–73.

    Article  CAS  PubMed  Google Scholar 

  10. Singh S, Poon R, Wong R, Metser U. 68Ga PET imaging in patients with neuroendocrine tumors: a systematic review and meta-analysis. Clin Nucl Med. 2018;43(11):802–10.

    Article  PubMed  Google Scholar 

  11. Hope TA, Bergsland EK, Bozkurt MF, Graham M, Heaney AP, Herrmann K, et al. Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors. J Nucl Med. 2018;59(1):66–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, et al. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med. 2011;52(12):1864–70.

    Google Scholar 

  13. Velikyan I, Sundin A, Sörensen J, Lubberink M, Sandström M, Garske-Román U, et al. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification. J Nucl Med. 2014;55(2):204–10.

    Article  CAS  PubMed  Google Scholar 

  14. Badiee S, Franc BL, Webb EM, Chu B, Hawkins RA, Coakley F. Role of IV iodinated contrast material in 18F-FDG PET/CT of liver metastases. Am J Roentgenol. 2008;191(5):1436–9.

    Article  Google Scholar 

  15. Ruf J, Heuck F, Schiefer J, Denecke T, Elgeti F, Pascher A, et al. Impact of multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors. Neuroendocrinology. 2010;91(1):101–9.

    Article  CAS  PubMed  Google Scholar 

  16. Schreiter NF, Maurer M, Pape U-F, Hamm B, Brenner W, Froeling V. Detection of neuroendocrine tumours in the small intestines using contrast-enhanced multiphase Ga-68 DOTATOC PET/CT: the potential role of arterial hyperperfusion. Radiol Oncol. 2014;48(2):120–6.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Kong G, Hofman MS, Murray WK, Wilson S, Wood P, Downie P, et al. Initial experience with gallium-68 DOTA-octreotate PET/CT and peptide receptor radionuclide therapy for pediatric patients with refractory metastatic neuroblastoma. J Pediatr Hematol Oncol. 2016;38(2):87–96.

    Article  CAS  PubMed  Google Scholar 

  18. Kroiss A, Putzer D, Uprimny C, Decristoforo C, Gabriel M, Santner W, et al. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine. Eur J Nucl Med Mol Imaging. 2011;38(5):865–73.

    Article  CAS  PubMed  Google Scholar 

  19. Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-d-Phe1,Tyr3-octreotate) and 18F-FDG. Cancer. 2008;112(11):2447–55.

    Article  PubMed  Google Scholar 

  20. Chan DL, Pavlakis N, Schembri GP, Bernard EJ, Hsiao E, Hayes A, et al. Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance. Theranostics. 2017;7(5):1149–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA. Eur J Nucl Med Mol Imaging. 2017;44(9):1588–601.

    Article  CAS  PubMed  Google Scholar 

  22. Souvatzoglou M, Ziegler SI, Martinez MJ, Busch R, Dzewas G, Schwaiger M, et al. Standardised uptake values from PET/CT images: comparison with conventional attenuation-corrected PET. Eur J Nucl Med Mol Imaging. 2007;34(3):405–12.

    Article  CAS  PubMed  Google Scholar 

  23. Montravers F, Grahek D, Kerrou K, Ruszniewski P, de Beco V, Aide N, et al. Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors? J Nucl Med. 2006;47(9):1455–62.

    CAS  PubMed  Google Scholar 

  24. Koopmans KP, Neels OC, Kema IP, Elsinga PH, Sluiter WJ, Vanghillewe K, et al. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol. 2008;26(9):1489–95.

    Article  PubMed  Google Scholar 

  25. Dromain C, Déandréis D, Scoazec J-Y, Goere D, Ducreux M, Baudin E, et al. Imaging of neuroendocrine tumors of the pancreas. Diagn Interv Imaging. 2016;97(12):1241–57.

    Article  CAS  PubMed  Google Scholar 

  26. Deleval N, Pesque L, Dieudonné A, Viry F, Hentic O, Lebtahi R, et al. Prognostic impact of bone metastases detected by 18F-DOPA PET in patients with metastatic midgut neuroendocrine tumors. Eur Radiol. 2021;31(6):4166–74.

    Article  PubMed  Google Scholar 

  27. Montravers F, Kerrou K, Nataf V, Huchet V, Lotz J-P, Ruszniewski P, et al. Impact of fluorodihydroxyphenylalanine-(18F) positron emission tomography on management of adult patients with documented or occult digestive endocrine tumors. J Clin Endocrinol Metab. 2009;94(4):1295–301.

    Article  CAS  PubMed  Google Scholar 

  28. de Mestier L, Lepage C, Baudin E, Coriat R, Courbon F, Couvelard A, et al. Digestive neuroendocrine neoplasms (NEN): French intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). Dig Liver Dis. 2020;52(5):473–92.

    Article  PubMed  Google Scholar 

  29. Kauhanen S, Seppänen M, Ovaska J, Minn H, Bergman J, Korsoff P, et al. The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors. Endocr Relat Cancer. 2009;16(1):255–65.

    Article  CAS  PubMed  Google Scholar 

  30. Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A. 18F-Fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res. 2010;16(3):978–85.

    Article  CAS  PubMed  Google Scholar 

  31. Becherer A, Szabó M, Karanikas G, Wunderbaldinger P, Angelberger P, Raderer M, et al. Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. J Nucl Med. 2004;45(7):1161–7.

    CAS  PubMed  Google Scholar 

  32. Ambrosini V, Tomassetti P, Castellucci P, Campana D, Montini G, Rubello D, et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging. 2008;35(8):1431–8.

    Article  CAS  PubMed  Google Scholar 

  33. Clift AK, Drymousis P, Al-Nahhas A, Wasan H, Martin J, Holm S, et al. Incidence of second primary malignancies in patients with neuroendocrine tumours. Neuroendocrinology. 2015;102(1–2):26–32.

    Article  CAS  PubMed  Google Scholar 

  34. Berends AMA, Kerstens MN, Bolt JW, Links TP, Korpershoek E, de Krijger RR, et al. False-positive findings on 6-[18F]fluor-l-3,4-dihydroxyphenylalanine PET (18F-FDOPA-PET) performed for imaging of neuroendocrine tumors. Eur J Endocrinol. 2018;179(2):125–33.

    Article  CAS  PubMed  Google Scholar 

  35. Johnbeck CB, Knigge U, Loft A, Berthelsen AK, Mortensen J, Oturai P, et al. Head-to-head comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: a prospective study of 59 patients with neuroendocrine tumors. J Nucl Med. 2017;58(3):451–7.

    Article  CAS  PubMed  Google Scholar 

  36. Pfeifer A, Knigge U, Binderup T, Mortensen J, Oturai P, Loft A, et al. 64Cu-DOTATATE PET for neuroendocrine tumors: a prospective head-to-head comparison with 111In-DTPA-octreotide in 112 patients. J Nucl Med. 2015;56(6):847–54.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nuclear Medicine Physician and Researcher, São Paulo State Cancer Institute–University of São Paulo Medical School (HCFMUSP), São Paulo, Brazil

    George Barberio Coura-Filho

  2. DIMEN Medicina Nuclear, São Paulo, Brazil

    Mayara Torres Silva de Oliveira

  3. DIMEN Medicina Nuclear, São Paulo, Brazil

    Ana Luiza Morais de Campos

Authors
  1. George Barberio Coura-Filho
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mayara Torres Silva de Oliveira
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ana Luiza Morais de Campos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to George Barberio Coura-Filho .

Rights and permissions

Reprints and permissions

Copyright information

© 2024 Der/die Autor(en), exklusiv lizenziert an Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Coura-Filho, G.B., Torres Silva de Oliveira, M., Morais de Campos, A.L. (2024). Positronen-Emissionstomographie bei neuroendokrinen Tumoren. In: Nuklearmedizin bei endokrinen Erkrankungen. Springer, Cham. https://doi.org/10.1007/978-3-031-47988-5_31

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-47988-5_31

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-47987-8

  • Online ISBN: 978-3-031-47988-5

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation